B+
Bull case
20%
Probability
Target price
$61.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
BSX
Boston ScientificANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-03
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+81.0
Score
AI commentary
News tone is mixed-positive: the official SEC-filed earnings release confirms a Q2 guidance beat, while secondary stored earnings-call coverage points to a lower near-term outlook. The packet does not provide a post-release price move or analyst revisions, and social data is absent; this supports monitoring rather than a high-conviction upgrade.
RankAlpha Sentiment Codex - 2026-08-03
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-07-29eventQ2 beat company guidanceMedium impact
The official Q2 earnings release reported $5.442 billion of revenue, up 7.5% reported and 7.0% organic, with adjusted EPS of $0.86 versus company guidance of $0.82-$0.84. The post-release price reaction is unavailable. [#SEC-8K-2026-07-29]
2026-08-31catalystWATCHMAN and electrophysiology pressureMedium impact
Secondary stored earnings-call coverage reports slower WATCHMAN demand and EP share pressure led management to lower the near-term outlook, with 2026 organic growth expected at 5%-6% and adjusted EPS at $3.28-$3.32. This has not been independently confirmed here against a full company transcript. [#PR-EARNINGS-2026-07-30]
2027-12-31catalystCardiovascular pipeline and strategic investmentsHigh impact
The official filing describes the $1.5 billion MiRus investment, an approximately 34% equity stake and an option on the MiRus TAVR business, alongside SEISMIQ and FARAPULSE clinical and product opportunities. [#SEC-8K-2026-07-29] [#SEC-8K-2026-04-22]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-03 • Updated nightlySource: Internal modelMethodology